戊酸雌二醇片/雌二醇环丙孕酮片在更年期综合征患者治疗中的应用效果分析  

Application effect analysis of estradiol valerate tablets/estradiol valerate and cyproterone acetate tablets in the treatment of patients with climacteric syndrome

作　　者：李继伟 LI Ji-wei(Tengzhou Xigang Central Health Center,Zaozhuang 277599,China)

机构地区：[1]滕州市西岗中心卫生院,277599

出　　处：《中国现代药物应用》2025年第6期107-110,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析对更年期综合征患者施以戊酸雌二醇片/雌二醇环丙孕酮片治疗的疗效。方法82例更年期综合征患者,采用抽签法分为治疗组和对照组,每组41例。治疗组患者施以戊酸雌二醇片/雌二醇环丙孕酮片治疗,对照组患者施以常规药物治疗。对比两组临床疗效、不良反应发生情况及治疗前后性激素[孕酮(P)、雌二醇(E2)、促黄体生成素(LH)、卵泡刺激素(FSH)]水平、Kupperman评分、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)]水平。结果治疗组临床总有效率97.56%明显高于对照组的80.49%(P<0.05)。治疗组治疗后P(3.82±0.16)nmol/L、E2(85.37±12.16)pmol/L明显高于对照组的(2.90±0.30)nmol/L、(76.40±12.30)pmol/L,LH(38.23±1.20)U/L、FSH(50.62±2.15)U/L明显低于对照组的(41.19±2.55)、(53.66±2.13)U/L(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。治疗组治疗后Kupperman评分(6.08±1.50)分低于对照组的(6.80±1.65)分(P<0.05)。治疗组治疗后TNF-α(12.46±1.20)pg/ml、IL-6(28.28±2.13)pg/ml、hs-CRP(12.65±1.13)mg/L低于对照组的(15.18±2.30)pg/ml、(35.50±3.20)pg/ml、(16.55±1.15)mg/L(P<0.05)。结论对更年期综合征患者施以戊酸雌二醇片/雌二醇环丙孕酮片治疗疗效良好,安全性较高,有利于性激素、症状、炎症因子的改善,建议推广。Objective To analyze the curative effect of estradiol valerate tablets/estradiol valerate and cyproterone acetate tablets in the treatment of patients with climacteric syndrome.Methods 82 patients with climacteric syndrome were divided into treatment group and control group by lottery method,with 41 cases in each group.Patients in the treatment group were treated with estradiol valerate tablets/estradiol valerate and cyproterone acetate tablets,and patients in the control group were treated with conventional drugs.Both groups were compared in terms of clinical efficacy,occurrence of adverse reactions,levels of sex hormones[progesterone(P),estradiol(E2),luteinizing hormone(LH),follicle stimulating hormone(FSH)],Kupperman score,inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),hypersensitive C-reactive protein(hs-CRP)]levels.Results The total effective rate of 97.56%in the treatment group was higher than 80.49%in the control group(P<0.05).After treatment,the treatment group had P of(3.82±0.16)nmol/L and E2 of(85.37±12.16)pmol/L,which were significantly higher than(2.90±0.30)nmol/L and(76.40±12.30)pmol/L in the control group;the treatment group had LH of(38.23±1.20)U/L and FSH of(50.62±2.15)U/L,which were significantly lower than(41.19±2.55) and (53.66±2.13) U/L in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). After treatment, Kupperman score of (6.08±1.50) points in the treatment group was lower than (6.80±1.65) points in the control group (P<0.05). After treatment, the treatment group had TNF-α of (12.46±1.20) pg/ml, IL-6 of (28.28±2.13) pg/ml and hs-CRP of (12.65±1.13) mg/L, which were lower than (15.18±2.30) pg/ml, (35.50±3.20) pg/ml and (16.55±1.15) mg/L in the control group (P<0.05). Conclusion The treatment of climacteric syndrome patients with estradiol valerate tablets/estradiol valerate and cyproterone acetate tablets has good efficacy and high safety, and is beneficial for the

关 键 词：更年期综合征 戊酸雌二醇片/雌二醇环丙孕酮片 性激素 炎症因子 

分 类 号：R711.75[医药卫生—妇产科学]